Hologic (NASDAQ:HOLX) Sets New 1-Year Low - Should You Sell?

Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) hit a new 52-week low during trading on Wednesday . The company traded as low as $60.03 and last traded at $60.33, with a volume of 192481 shares trading hands. The stock had previously closed at $61.38.

Analyst Upgrades and Downgrades

Several research firms have recently commented on HOLX. Raymond James reissued an "outperform" rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Argus cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. William Blair reiterated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Morgan Stanley decreased their price objective on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Finally, Royal Bank of Canada dropped their price target on Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Hologic currently has a consensus rating of "Hold" and a consensus price target of $84.62.

Hologic Stock Up 0.7 %

The stock's fifty day moving average is $64.30 and its two-hundred day moving average is $72.52. The firm has a market cap of $13.75 billion, a P/E ratio of 19.33, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Remove Ads

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Institutional Investors Weigh In On Hologic

Large investors have recently added to or reduced their stakes in the company. General Partner Inc. bought a new stake in Hologic in the fourth quarter worth $26,000. Groupama Asset Managment increased its stake in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 2,999 shares during the period. Venturi Wealth Management LLC raised its holdings in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after buying an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.